Company Information - Shandong Heda announced that its director and vice general manager, Bi Songling, plans to reduce his shareholding by up to 350,000 shares, which represents 0.1017% of the company's total share capital, within three months after 15 trading days from the announcement date [1] - As of the report, Shandong Heda has a market capitalization of 4.6 billion yuan [1] Revenue Composition - For the first half of 2025, Shandong Heda's revenue composition is as follows: cellulose ether accounts for 72.98%, plant capsules account for 21.1%, other trade chemical products account for 3.86%, graphite chemical equipment accounts for 1.9%, and other businesses account for 0.16% [1]

Company Summary - Shandong Heda announced a share buyback plan, repurchasing approximately 2.43 million shares, which accounts for 0.6973% of the total share capital, with a total expenditure of about 29.93 million yuan [1] - The highest transaction price during the buyback was approximately 14.29 yuan per share, while the lowest was 11.1 yuan per share [1] - As of the report date, Shandong Heda's market capitalization stands at 4.6 billion yuan [1] Revenue Composition - For the first half of 2025, Shandong Heda's revenue composition is as follows: cellulose ether accounts for 72.98%, plant capsules for 21.1%, other trade chemical products for 3.86%, graphite chemical equipment for 1.9%, and other businesses for 0.16% [1]

Core Insights - The report highlights the significant growth potential in the direct air capture (DAC) technology sector, particularly following the inclusion of two key projects in Shanghai's 2025 key technology research plan, indicating strong government support and market potential for DAC materials and equipment [6][7]. Market Trends - The domestic market indices showed slight fluctuations, with the Shanghai Composite Index closing at 3,812.22, up by 0.13%, while the ChiNext Index saw a more substantial increase of 1.27% [4]. Industry Commentary - In the chemical raw materials sector, the new materials index experienced a decline of 0.31%, underperforming against the ChiNext Index by 2.67%. Specific segments such as semiconductor materials and electronic chemicals saw notable decreases of 4.74% and 1.54%, respectively, while battery chemicals surged by 13.36% [6]. - The report provides a detailed weekly price tracking of various materials, indicating price changes in amino acids, biodegradable materials, vitamins, industrial gases, and plastics, with notable price stability in biodegradable materials and vitamins [6]. Company Analysis - For Weilon Delicious (卫龙美味), the company reported a total revenue of 3.483 billion yuan for the first half of 2025, reflecting an 18.5% year-on-year growth, with a net profit of 736 million yuan, also up by 18.5% [11]. - The growth in Weilon Delicious is attributed to the expansion of vegetable products, particularly konjac products, which benefited from health food trends. The company is also optimizing its product structure and has plans to introduce new products [11]. - The company’s gross margin decreased by 2.6 percentage points to 47.2% due to rising raw material costs, but effective cost control measures helped maintain a net profit margin of 21.1% [11]. Investment Recommendations - The report suggests focusing on the DAC technology sector, particularly on key materials and equipment suppliers such as Blue Sky Technology and Xijiao Co., as the market for DAC is expected to grow significantly with government backing [7]. - For Weilon Delicious, the projected earnings per share (EPS) for 2025-2027 are estimated at 0.51, 0.62, and 0.79 yuan, with corresponding price-to-earnings (PE) ratios of 21.5, 17.6, and 13.8, indicating a strong growth trajectory in the spicy snack food sector [11].

Report Industry Investment Rating - Not mentioned in the provided content Core Viewpoints - The Hedda Convertible Bond (127088.SZ) is a high - quality balanced bond with the issuer's performance and valuation at a low level. The company has excellent fundamentals, and its performance and valuation are at historical lows. The bond has a long remaining term [1][4] - Based on the Shanxi Securities convertible bond valuation model, if the stock price remains unchanged, without considering forced redemption and downward revision, the reasonable valuation of the Hedda Convertible Bond is between 124 and 132 yuan [5] Summary by Relevant Catalogs Information about the Convertible Bond - The Hedda Convertible Bond has a rating of AA - a bond balance of 600 million yuan, accounting for 99.97% of the total issuance. The remaining term is 3.82 years. The latest closing price is 122.79 yuan, the conversion premium rate is 50.15%, and the pure bond premium rate is 14.83% [1] Information about the Underlying Stock - The underlying stock is Shandong Hedda (002810.SZ), established in 1992. Its main products are cellulose ether and plant capsules, and its business covers more than 100 countries and regions. The latest total market value is 4.797 billion yuan, and the 2025E PE is 26.3x. The actual controller is an individual, and the largest shareholder and persons acting in concert hold a total of 39.87% of the shares. The attributable net profit in H125 decreased by 8.71% year - on - year [2] Main Highlights of the Hedda Convertible Bond - The company has been deeply involved in the cellulose ether industry for nearly 30 years. Cellulose ether has many advantages. The company's products cover more than 70 categories and more than 100 models, with rich structure and leading technology. By the end of H125, its wholly - owned subsidiary Zhongfu Hedda had a production capacity of 10,000 MT and was one of the largest HEC manufacturers in China [3] - The company has extended its industrial chain to the downstream plant capsule industry. Compared with gelatin capsules, plant capsules have many advantages and are mainly used in the steadily growing health product industry. By the end of H125, the company's effective production capacity was 30 billion capsules, with a capacity utilization rate of about 60%. The US factory with a planned capacity of 20 billion capsules is under construction and is expected to be put into production in the middle of next year [4] - The company has a high proportion of overseas revenue. In 2024, the export proportions of building - grade, pharmaceutical and food - grade cellulose ether, and plant capsules were 56.4%, 57.3%, and 88.2% respectively. In 2025, the US imposed anti - dumping duties on some of the company's products, affecting orders and increasing raw material costs. Currently, the company is actively responding, and the unreasonable factors may ease in Q4, when the performance is expected to turn around [4]

Group 1 - The company Shandong Heda announced a share buyback plan, repurchasing approximately 1.78 million shares, which accounts for about 0.5106% of its total share capital, with a total transaction amount of approximately 21.13 million yuan [1] - The highest transaction price during the buyback was approximately 14.29 yuan per share, while the lowest was 11.1 yuan per share [1] - As of the report date, Shandong Heda's market capitalization is 4.9 billion yuan [1] Group 2 - For the first half of 2025, Shandong Heda's revenue composition is as follows: cellulose ether accounts for 72.98%, plant capsules 21.1%, other trade chemical products 3.86%, graphite chemical equipment 1.9%, and other businesses 0.16% [1]

Core Insights - The company reported a revenue of 972 million yuan for the first half of 2025, representing a year-on-year increase of 3.91%, while the net profit attributable to the parent company was 113 million yuan, a decrease of 8.71% [1] - In the second quarter of 2025, the company achieved a revenue of 505 million yuan, a slight decline of 0.99% year-on-year, with a net profit of 67.97 million yuan, down 3.35% year-on-year [1] - For the year 2024, the company experienced significant growth, with total revenue reaching 1.957 billion yuan, an increase of 25.72%, and a net profit of 222 million yuan, up 0.65% [1] - The company signed an exclusive agency agreement with IMCD, a global leader in chemical distribution, to enhance its global presence [1] Business Strategy - The company plans to invest in a plant capsule project in the U.S. with a capacity of 20 billion capsules per year, aiming to strengthen its market share and pricing power in the U.S. and surrounding markets [2] - The investment is capped at 500 million yuan and will be funded through internal resources or external financing, with a construction period of approximately 20 months, targeting completion by 2026 [2] - This project aligns with industry trends and is seen as a necessary step for the company's sustainable global development strategy [2] Financial Projections - Revenue forecasts for 2025 to 2027 are 2.325 billion yuan, 2.488 billion yuan, and 2.724 billion yuan, respectively, with net profits projected at 229 million yuan, 283 million yuan, and 352 million yuan [2] - The expected earnings per share (EPS) for the same period are 0.66 yuan, 0.81 yuan, and 1.01 yuan, with corresponding price-to-earnings (PE) ratios of 21.6x, 17.4x, and 14.0x [2]

Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 972 million yuan, a year-on-year increase of 4%, and a net profit attributable to shareholders of 113 million yuan, a year-on-year decrease of 9% [1] - In Q2 2025, the company reported revenue of 505 million yuan, a year-on-year increase of 1%, and a net profit attributable to shareholders of 68 million yuan, a year-on-year decrease of 3% [1] - The company plans to distribute a cash dividend of 1 yuan for every 10 shares [1] Group 2: Industry Position and Product Development - The company is a global leader in cellulose ether, which is widely used in construction materials, pharmaceuticals, food, aerospace, and new energy batteries [2] - The company established a subsidiary, Hershey, in 2014 to enter the plant capsule industry, achieving an integrated supply chain from cellulose ether to plant capsules [2] - By the end of 2024, the company's production capacity for cellulose ether and plant capsules is expected to reach 74,000 tons and 35 billion capsules, respectively, with an additional 15 billion capsules under construction [2] Group 3: Market Expansion and Strategic Initiatives - In the first half of 2025, the company's export revenue accounted for 65% of total revenue, with a year-on-year increase of 9% to 630 million yuan, and the gross margin for exports is significantly higher than for domestic sales [2] - In May 2025, the company signed an exclusive agency agreement with Univar Solutions to expand its pharmaceutical-grade cellulose ether distribution to Europe, accelerating its global layout [2] - The company is responding to the U.S. anti-dumping measures by planning to invest in a plant capsule project in the U.S. with a capacity of 20 billion capsules per year, with an investment not exceeding 500 million yuan [3] Group 4: Future Outlook - The company expects net profits attributable to shareholders for 2025-2027 to be 221 million, 339 million, and 427 million yuan, respectively, and has initiated coverage with a "recommend" rating [4]

Group 1 - The core viewpoint of the article is that Shandong Heda announced the results of its board meeting and provided insights into its revenue composition for the first half of 2025 [1] - Shandong Heda's revenue for the first half of 2025 is primarily composed of cellulose ether, accounting for 72.98%, followed by plant capsules at 21.1%, other trade chemical products at 3.86%, graphite chemical equipment at 1.9%, and other businesses at 0.16% [1] - As of the report, Shandong Heda has a market capitalization of 4.8 billion yuan [1] Group 2 - The article mentions that the A-share market has seen trading volumes exceed 2 trillion yuan for eight consecutive days, indicating a robust trading environment [1] - The recruitment activities by major brokerage firms are highlighted, with 25 job positions available, reflecting the industry's demand for talent [1]

Core Viewpoint - Shandong Heda announced that its board meeting on August 8, 2025, reviewed the proposal regarding not adjusting the conversion price of "Heda Convertible Bonds" [2] Financial Performance - For the year 2024, Shandong Heda's revenue composition is as follows: - Cellulose ether: 71.32% - Plant capsules: 20.96% - Trade chemical products - others: 4.87% - Graphite chemical equipment: 1.56% - Diacetone acrylamide: 0.98% [2]

Core Viewpoint - The company, Shandong Heda Group Co., Ltd., is changing part of the fundraising purpose from the issuance of convertible bonds to permanently supplement working capital, which is deemed necessary for its operational needs and will not adversely affect other investment projects [1][5][9]. Fundraising Overview - The company was approved to issue 6 million convertible bonds with a total fundraising amount of 600 million RMB, netting approximately 592.75 million RMB after deducting issuance costs [1][2]. - As of June 30, 2025, the company has utilized approximately 457.47 million RMB of the raised funds, leaving a balance of about 135.76 million RMB [2][4]. Fund Usage Details - The remaining funds include 120 million RMB that was temporarily used to supplement working capital and has since been returned [2][4]. - The company plans to terminate the investment project for "Hershey's annual production of 15 billion plant capsules and intelligent three-dimensional warehouse upgrade project," which was initially planned for an investment of 181.68 million RMB [5][6]. Reasons for Fund Usage Change - The decision to halt the aforementioned project is influenced by changes in the international situation and market environment, which have affected the project's feasibility [5][6]. - The remaining funds will be used for daily operations and business development, enhancing the efficiency of fund usage and alleviating financial pressure [5][8]. Impact of Fund Usage Change - The change in fund usage is considered a prudent adjustment that aligns with the company's operational needs and will not negatively impact other investment projects [5][8]. - The company aims to optimize resource allocation and reduce financial costs, thereby improving operational efficiency and safeguarding the interests of the company and its investors [8][9]. Approval Process - The board of directors and the supervisory board have approved the change in fund usage, which will be submitted for further approval at the shareholders' meeting and the bondholders' meeting [8][9].